Disruption of the HIV-1 protease dimer with interface peptides: structural studies using NMR spectroscopy combined with [2-(13)C]-Trp selective labeling.

HIV-1 protease (HIV-1 PR), which is encoded by retroviruses, is required for the processing of gag and pol polyprotein precursors, hence it is essential for the production of infectious viral particles. In vitro inhibition of the enzyme results in the production of progeny virions that are immature and noninfectious, suggesting its potential as a therapeutic target for AIDS. Although a number of potent protease inhibitor drugs are now available, the onset of resistance to these agents due to mutations in HIV-1 PR has created an urgent need for new means of HIV-1 PR inhibition. Whereas enzymes are usually inactivated by blocking of the active site, the structure of dimeric HIV-1 PR allows an alternative inhibitory mechanism. Since the active site is formed by two half-enzymes, which are connected by a four-stranded antiparallel beta-sheet involving the N- and C- termini of both monomers, enzyme activity can be abolished by reagents targeting the dimer interface in a region relatively free of mutations would interfere with formation or stability of the functional HIV-1 PR dimer. This strategy has been explored by several groups who targeted the four-stranded antiparallel beta-sheet that contributes close to 75% of the dimerization energy. Interface peptides corresponding to native monomer N- or C-termini of several of their mimetics demonstrated, mainly on the basis of kinetic analyses, to act as dimerization inhibitors. However, to the best of our knowledge, neither X-ray crystallography nor NMR structural studies of the enzyme-inhibitor complex have been performed to date. In this article we report a structural study of the dimerization inhibition of HIV-1 PR by NMR using selective Trp side chain labeling.

[1]  Kurt Wüthrich,et al.  Nmr in drug discovery , 2002, Nature Reviews Drug Discovery.

[2]  G. Wagner,et al.  NMR solution structure of the antitumor compound PT523 and NADPH in the ternary complex with human dihydrofolate reductase. , 1997, Biochemistry.

[3]  E. Reddy,et al.  HTLV-III gag protein is processed in yeast cells by the virus pol-protease. , 1986, Science.

[4]  I. Weber.  Comparison of the crystal structures and intersubunit interactions of human immunodeficiency and Rous sarcoma virus proteases. , 1990, The Journal of biological chemistry.

[5]  Maurizio Pellecchia,et al.  Use of selective Trp side chain labeling to characterize protein-protein and protein-ligand interactions by NMR spectroscopy. , 2003, Journal of the American Chemical Society.

[6]  T. Yamazaki,et al.  Secondary structure and signal assignments of human-immunodeficiency-virus-1 protease complexed to a novel, structure-based inhibitor. , 1994, European journal of biochemistry.

[7]  Shultz,et al.  Small-Molecule Inhibitors of HIV-1 Protease Dimerization Derived from Cross-Linked Interfacial Peptides This work was supported by NIH (GM52739) and NSF (9457372-CHE). , 2000, Angewandte Chemie.

[8]  P. Wingfield,et al.  Regulation of HIV-1 protease activity through cysteine modification. , 1996, Biochemistry.

[9]  J. Beijnen,et al.  Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir , 1997, Pharmacy World and Science.

[10]  L J Davis,et al.  Active human immunodeficiency virus protease is required for viral infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[11]  W Schramm,et al.  The inhibition of human immunodeficiency virus proteases by 'interface peptides'. , 1996, Antiviral research.

[12]  Angela M Gronenborn,et al.  Solution Structure of the Mature HIV-1 Protease Monomer , 2003, Journal of Biological Chemistry.

[13]  William R. Taylor,et al.  A structural model for the retroviral proteases , 1987, Nature.

[14]  W. Howe,et al.  The HIV-1 protease as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties. , 1994, Biochemistry.

[15]  Renaldo Mendoza,et al.  NMR-Based Screening of Proteins Containing 13C-Labeled Methyl Groups , 2000 .

[16]  B. Ho,et al.  Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity , 1989, Journal of virology.

[17]  Michiel Van Gool,et al.  Dimerization inhibitors of HIV-1 protease based on a bicyclic guanidinium subunit. , 2003, Journal of Medicinal Chemistry.

[18]  C. Craik,et al.  Regulation of autoproteolysis of the HIV-1 and HIV-2 proteases with engineered amino acid substitutions. , 1993, The Journal of biological chemistry.

[19]  A. Simon,et al.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. , 2000, Science.

[20]  W. Schramm,et al.  Lipopeptides as Dimerization Inhibitors of HIV-1 Protease , 1999, Biological chemistry.

[21]  A. Gronenborn,et al.  Folded Monomer of HIV-1 Protease* , 2001, The Journal of Biological Chemistry.

[22]  G C Roberts,et al.  NMR spectroscopy in structure-based drug design. , 1999, Current opinion in biotechnology.

[23]  Angela M Gronenborn,et al.  Revisiting Monomeric HIV-1 Protease , 2003, The Journal of Biological Chemistry.

[24]  I. Weber,et al.  Comparative analysis of the sequences and structures of HIV‐1 and HIV‐2 proteases , 1991, Proteins.

[25]  R. Heinrikson,et al.  Dissociative inhibition of dimeric enzymes. Kinetic characterization of the inhibition of HIV-1 protease by its COOH-terminal tetrapeptide. , 1991, The Journal of biological chemistry.

[26]  B. Stockman.  NMR spectroscopy as a tool for structure-based drug design , 1998 .

[27]  R. Zutshi,et al.  TARGETING THE DIMERIZATION INTERFACE OF HIV-1 PROTEASE: INHIBITION WITH CROSS-LINKED INTERFACIAL PEPTIDES , 1997 .

[28]  M. Reboud-Ravaux,et al.  Dimerization Inhibitors of HIV-1 Protease , 2002, Biological chemistry.